This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571)

Published on in Vol 7, No 10 (2018): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/11218, first published .
The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study

The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study

The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study

Authors of this article:

Thomas Langford1 Author Orcid Image ;   Zehra Arkir2 Author Orcid Image ;   Anastasia Chalkidou1 Author Orcid Image ;   Kate Goddard1 Author Orcid Image ;   Lamprini Kaftantzi1 Author Orcid Image ;   Mark Samaan3 Author Orcid Image ;   Peter Irving3 Author Orcid Image
Article Authors Cited by (2) Tweetations (3) Metrics

Journals

  1. Marquez-Megias S, Nalda-Molina R, Sanz-Valero J, Más-Serrano P, Diaz-Gonzalez M, Candela-Boix M, Ramon-Lopez A. Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. Pharmaceutics 2022;14(5):1009 View
  2. Alsoud D, Moes D, Wang Z, Soenen R, Layegh Z, Barclay M, Mizuno T, Minichmayr I, Keizer R, Wicha S, Wolbink G, Lambert J, Vermeire S, de Vries A, Papamichael K, Padullés-Zamora N, Dreesen E. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring 2024;46(3):291 View